Abstract burst of orange and blue light particles

Delivering an Integrated Summary of Safety: Resolving Data Inconsistencies and Complex Derivations to Support Regulatory Submission 

1 minute read

Published: October 22nd, 2025

Phastar supported a sponsor in preparing an Integrated Summary of Safety (ISS) for an investigational drug in sickle cell disease, pooling data from three studies: two Phase 3 randomized trials (single- and multiple-dose) and one open-label extension. 

Key Challenges: 

  • Inconsistent ADaM Structures: Critical domains (ADSL, ADLB, ADAE, ADVS) required reconciliation. 
  • Varying Safety Set Definitions: Differences across studies complicated treatment and baseline flag creation. 
  • Complex Derived Variables: ADAE derivations demanded strict adherence to coding standards. 
  • Compliance Calculation Discrepancies: Divergent approaches had to be standardized. 
  • MedDRA Up-Versioning: Two up-versioning steps were required for consistent adverse event coding. 

Our Approach: 

  • Standardized ADaM structures across all studies. 
  • Implemented flexible flagging logic to accommodate differing safety sets. 
  • Designed robust logic for complex ADAE derivations, ensuring consistent adverse event capture. 
  • Aligned compliance calculations with a body weight–adjusted formula. 
  • Managed MedDRA up-versioning to maintain data integrity. 
  • Maintained strong client engagement with weekly operational meetings to ensure rapid issue resolution and alignment. 

    Complete the form to read the full case study

Related articles

From Rescue Study to Strategic Partnership: Accelerating Regulatory Submission Through Reliable Statistical Delivery

From Rescue Study to Strategic Partnership: Accelerating Regulatory Submission Through Reliable Statistical Delivery

November 16th, 2026 1 minute read

When clinical development programs face quality concerns, resource shortages, or submission risks, sponsors need a pa...

Turning a Failed Bioequivalence Study into a Successful Regulatory Outcome 

Turning a Failed Bioequivalence Study into a Successful Regulatory Outcome 

November 16th, 2026 1 minute read

When a bioequivalence study fails to meet regulatory criteria, understanding why is critical for successful developme...

Independent DMC Support and Interim Analysis for an ALS Clinical Trial 

Independent DMC Support and Interim Analysis for an ALS Clinical Trial 

November 16th, 2026 1 minute read

Data Monitoring Committees play a vital role in safeguarding patient safety and supporting informed decision-making t...